COSIMO – patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study

被引：0
作者：
Alexander T. Cohen
Anthony Maraveyas
Jan Beyer-Westendorf
Agnes Y. Y. Lee
Lorenzo G. Mantovani
Miriam Bach
机构：
[1] King’s College London,Department of Haematological Medicine, Guys and St Thomas’ NHS Foundation Trust
[2] Castle Hill Hospital,Joint Centre for Cancer Studies, Hull York Medical School, QCOH
[3] University Hospital “Carl Gustav Carus” Dresden,Thrombosis Research Unit, Department of Medicine I, Division Hematology
[4] Kings College London,Kings Thrombosis Service, Department of Haematology
[5] University of British Columbia,Division of Hematology
[6] British Columbia Cancer Agency,CESP
[7] University of Milan Bicocca,Center for Public Health Research
[8] Bayer AG,undefined
来源：
Thrombosis Journal | / 16卷
关键词：
Active cancer; Health-related quality of life; Low molecular weight heparin; Patient preference; Recurrent venous thromboembolism; Rivaroxaban; Vitamin K antagonist;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 221 条
  • [1] Ay C(2017)Cancer-associated venous thromboembolism: burden, mechanisms, and management Thromb Haemost 117 219-230
  • [2] Pabinger I(2012)Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis PLoS Med. 9 57-65
  • [3] Cohen AT(2017)Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study Thromb Haemost. 117 632-634
  • [4] Horsted F(2007)Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy J Thromb Haemost. 5 3484-3488
  • [5] West J(2002)Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis Blood. 100 146-153
  • [6] Grainge MJ(2003)Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer N Engl J Med. 349 677-686
  • [7] Cohen AT(2015)Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial JAMA. 314 1028-1035
  • [8] Katholing A(2015)Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study J Thromb Haemost. 13 337-345
  • [9] Rietbrock S(2015)Patients' Experiences of LIving with CANcer-associated thrombosis: the PELICAN study Patient Prefer Adherence. 9 715-722
  • [10] Bamber L(2005)Malignancies, prothrombotic mutations, and the risk of venous thrombosis JAMA. 293 24-vi92
12345678910